net/publication/263317220
CITATIONS READS
2 397
1 author:
Tomoko Ishizu
University of Tsukuba
192 PUBLICATIONS 1,742 CITATIONS
SEE PROFILE
All content following this page was uploaded by Tomoko Ishizu on 05 January 2016.
Journal of Cardiology
journal homepage: www.elsevier.com/locate/jjcc
Editorial
http://dx.doi.org/10.1016/j.jjcc.2014.05.003
0914-5087/ß 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
[(Fig._1)TD$IG] Editorial / Journal of Cardiology 64 (2014) 250–252 251
Fig. 1. Pathophysiological relation between COPD and heart failure. COPD, chronic obstructive pulmonary disease; RAS, renin–angiotensin system.
Skeletal muscle atrophy is pathogenetically important in both The establishment of an appropriate approach to managing
COPD and HF [10]. Systemic inflammation is responsible for the HF accompanied with COPD is needed. In this strategy, we
skeletal muscle alternation. should try to improve quality of life as well as survival of these
There have been few prospective studies into combined patients.
treatment of COPD and HF. Therefore, in COPD patients, HF should
be treated according to usual HF guidelines as there is no evidence
that HF should be treated differently in the presence of this References
respiratory disease. Statins and renin–angiotensin system (RAS)
[1] Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and
blockers may reduce the morbidity and mortality of COPD patients.
COPD: partners in crime? Respirology 2010;15:895–901.
Statins and RAS inhibitors may affect the baseline inflammation [6]. [2] Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart
The effects of beta-blockers should be clarified according to the failure and chronic obstructive pulmonary disease: diagnostic pitfalls and
severity of airway limitation in stable patients who have HF and epidemiology. Eur J Heart Fail 2009;11:130–9.
[3] Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y, Yamauchi H, Iwaya S,
coexisting COPD. Beta2-blockade in severe airway obstruction Owada T, Miyata M, Abe S, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki
should be avoided due to bronchial spasm in acute decompensated T, Sugimoto K, et al. Cardiovascular function and prognosis of patients with
phase. Importantly, Yoshihisa et al. [3] clearly demonstrated the heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol
2014;64:256–64.
beneficial effect of beta-blockers in mild and moderate COPD for [19_TD$IF][4] Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence
chronic management of HF on 3-year all-cause mortality. The with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug
results suggest the encouraging use of beta-blockers as standard therapy guidelines: a retrospective actuarial claims data analysis. Curr Med
Res Opin 2011;27:1425–9.
therapy regardless of the presence of moderate comorbid COPD. [5] Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G,
However, the prescription rate of beta-blockers was as low as 58% Arakaki D, Laffaye N, Fuselli JJ, Massolin HP, Gambarte J, Romero M, Tognoni
in moderate COPD compared to non-COPD of 79% in this G. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012;39:51–8.
[6] de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R. The association
observational study. Therapy with beta-blockers may be withheld
between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon
in COPD patients due to concerns of the diminution of the beta2- Dis 2013;8:305–12.
agonist bronchodilator effect and the worsening of bronchospasm. [7] Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardio-
vascular disease, part II: pathophysiology, clinical importance, and manage-
However, there have been several reports supporting the beneficial
ment of right ventricular failure. Circulation 2008;117:1717–31.
effects of beta-blockers in COPD patients with HF, and the selective [8] Louie EK, Rich S, Levitsky S, Brundage BH. Doppler echocardiographic demon-
beta1-blocker bisoprolol is recommended in the European Society stration of the differential effects of right ventricular pressure and volume
of Cardiology guidelines [11]. A further prospective trial is needed overload on left ventricular geometry and filling. J Am Coll Cardiol 1992;19:
84–90.
in the future. We do not hesitate to start low-dose beta-blocker and [9] Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer
try titrating up in patients with COPD in present clinical practice. In DB, Levy D, Wilson PW, D’Agostino RB, Framingham Heart Study. Inflamma-
addition, caution should be advised with the use of inhaled beta2- tory markers and risk of heart failure in elderly subjects without prior
myocardial infarction: the Framingham Heart Study. Circulation 2003;107:
agonists for the treatment of COPD in patients with HF at present, 1486–91.
because there have been some reports that inhaled beta-agonist [10] Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM.
increases death and hospital admissions [12]. Striking similarities in systemic factors contributing to decreased exercise
252 Editorial / Journal of Cardiology 64 (2014) 250–252
capacity in patients with severe chronic heart failure or COPD. Chest Tomoko Ishizu (MD, FJCC)*
2003;123:1416–24.
[11] Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole- Department of Clinical Laboratory Medicine, Faculty of Medicine,
Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, University of Tsukuba, Ibaraki, Japan
Mebazaa A, Nieminen M, Priori SG, Swedberg K, et al. [20_TD$IF]ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008: the Task
*Correspondence to: 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575,
Force for the diagnosis and treatment of acute and chronic heart failure 2008
of the European Society of Cardiology[21_TD$IF][. Developed in collaboration with the Japan. Tel.: +81 29 853 3142; fax: +81 29 853 3143
Heart Failure Association of the ESC (HFA) and endorsed by the European E-mail address: tomoco@md.tsukuba.ac.jp (T. Ishizu).
Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–89.
[12] Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality
and heart failure exacerbations associated with inhaled beta-adrenoceptor 7 May 2014
agonists among patients with known left ventricular systolic dysfunction. Available online 21 June 2014
Chest 2003;123:1964–9.